Paricalcitol
featured

We are open as normal during COVID-19 pandemic. Order online, same day shipping out.

    WARNING: This product is for research use only, not for human or veterinary use.

MedKoo CAT#: 318457

CAS#: 131918-61-1

Description: Paricalcitol, marketed by Abbott Laboratories under the trade name Zemplar, is a drug used for the prevention and treatment of secondary hyperparathyroidism associated with chronic renal failure. It is an analog of 1,25-dihydroxyergocalciferol, the active form of vitamin D2. Paricalcitol binds to the vitamin D receptor and has been shown to reduce parathyroid hormone levels. This agent also increases the expression of PTEN ('Phosphatase and Tensin homolog deleted on chromosome Ten'), a tumor-suppressor gene, in leukemic cells and cyclin-dependent kinase inhibitors.


Price and Availability

Size Price Shipping out time Quantity
1mg USD 350 2 Weeks
5mg USD 1250 2 Weeks
Inquire bulk and customized quantity

Pricing updated 2020-07-11. Prices are subject to change without notice.

Paricalcitol, purity > 98%, is in stock. Current shipping out time is about 2 weeks after order is received. CoA, QC data and MSDS documents are available in one week after order is received.


Chemical Structure

img

Theoretical Analysis

MedKoo Cat#: 318457
Name: Paricalcitol
CAS#: 131918-61-1
Chemical Formula: C27H44O3
Exact Mass: 416.32905
Molecular Weight: 416.64
Elemental Analysis: C, 77.83; H, 10.64; O, 11.52


Synonym: Paricalcitol; Zemplar; Compound 49510; 19-Nor-1alpha,25-dihydroxyvitamin D2; Paracalcin; Abbott brand of paricalcitol; paricalcitol; paricalcitol-d6; Zemplar;

IUPAC/Chemical Name: (1R,3R)-5-(2-((1R,3aS,7aR,E)-1-((2R,5S,E)-6-hydroxy-5,6-dimethylhept-3-en-2-yl)-7a-methyloctahydro-4H-inden-4-ylidene)ethylidene)cyclohexane-1,3-diol

InChi Key: BPKAHTKRCLCHEA-UBFJEZKGSA-N

InChi Code: InChI=1S/C27H44O3/c1-18(8-9-19(2)26(3,4)30)24-12-13-25-21(7-6-14-27(24,25)5)11-10-20-15-22(28)17-23(29)16-20/h8-11,18-19,22-25,28-30H,6-7,12-17H2,1-5H3/b9-8+,21-11+/t18-,19+,22-,23-,24-,25+,27-/m1/s1

SMILES Code: O[C@@H](C[C@H](O)C/1)CC1=C\C=C2CCC[C@@]3(C)[C@@]/2([H])CC[C@]3([H])[C@H](C)/C=C/[C@H](C)C(C)(O)C


Technical Data

Appearance:
Solid powder

Purity:
>98% (or refer to the Certificate of Analysis)

Shipping Condition:
Shipped under ambient temperature as non-hazardous chemical. This product is stable enough for a few weeks during ordinary shipping and time spent in Customs.

Storage Condition:
Dry, dark and at 0 - 4 C for short term (days to weeks) or -20 C for long term (months to years).

Solubility:
Soluble in DMSO, not in water

Shelf Life:
>2 years if stored properly

Drug Formulation:
This drug may be formulated in DMSO

Stock Solution Storage:
0 - 4 C for short term (days to weeks), or -20 C for long term (months).

HS Tariff Code:
2934.99.9001


References

1: Bulut G, Basbugan Y, Ari E, Erten R, Bektas H, Alp HH, Bayram I. Paricalcitol
may improve oxidative DNA damage on experimental amikacin-induced nephrotoxicity
model. Ren Fail. 2016 Mar 16:1-8. [Epub ahead of print] PubMed PMID: 26983906.

2: Lee AS, Jung YJ, Thanh TN, Lee S, Kim W, Kang KP, Park SK. Paricalcitol
attenuates lipopolysaccharide-induced myocardial inflammation by regulating the
NF-κB signaling pathway. Int J Mol Med. 2016 Mar 4. doi: 10.3892/ijmm.2016.2516.
[Epub ahead of print] PubMed PMID: 26954764; PubMed Central PMCID: PMC4790655.

3: Cai P, Tang X, Qin W, Ji L, Li Z. Comparison between paricalcitol and active
non-selective vitamin D receptor activator for secondary hyperparathyroidism in
chronic kidney disease: a systematic review and meta-analysis of randomized
controlled trials. Int Urol Nephrol. 2016 Apr;48(4):571-84. doi:
10.1007/s11255-015-1195-6. Epub 2016 Jan 9. PubMed PMID: 26748501.

4: Riera M, Anguiano L, Clotet S, Roca-Ho H, Rebull M, Pascual J, Soler MJ.
Paricalcitol modulates ACE2 shedding and renal ADAM17 in NOD mice beyond
proteinuria. Am J Physiol Renal Physiol. 2016 Mar 15;310(6):F534-46. doi:
10.1152/ajprenal.00082.2015. Epub 2015 Dec 23. PubMed PMID: 26697977.

5: Egido J, Martínez-Castelao A, Bover J, Praga M, Torregrosa JV,
Fernández-Giráldez E, Solozábal C. The pleiotropic effects of paricalcitol:
Beyond bone-mineral metabolism. Nefrologia. 2016 Jan-Feb;36(1):10-18. doi:
10.1016/j.nefro.2015.11.003. Epub 2015 Dec 23. English, Spanish. PubMed PMID:
26705959.

6: Afsar B, Agca E, Turk S. Comparison of erythropoietin resistance in
hemodialysis patients using calcitriol, cinacalcet, or paricalcitol. J Clin
Pharmacol. 2015 Nov;55(11):1280-5. doi: 10.1002/jcph.556. Epub 2015 Jul 14.
PubMed PMID: 26032009.

7: Ekart R, Bevc S, Hojs R, Hojs N. Proteinuria and albuminuria during and after
paricalcitol treatment in chronic kidney disease patients. J Clin Pharmacol. 2015
Oct 14. doi: 10.1002/jcph.660. [Epub ahead of print] PubMed PMID: 26465921.

8: Husain K, Suarez E, Isidro A, Hernandez W, Ferder L. Effect of paricalcitol
and enalapril on renal inflammation/oxidative stress in atherosclerosis. World J
Biol Chem. 2015 Aug 26;6(3):240-8. doi: 10.4331/wjbc.v6.i3.240. PubMed PMID:
26322179; PubMed Central PMCID: PMC4549765.

9: Dáňová K, Klapetková A, Kayserová J, Šedivá A, Špíšek R, Jelínková LP. NF-κB,
p38 MAPK, ERK1/2, mTOR, STAT3 and increased glycolysis regulate stability of
paricalcitol/dexamethasone-generated tolerogenic dendritic cells in the
inflammatory environment. Oncotarget. 2015 Jun 10;6(16):14123-38. PubMed PMID:
26053099; PubMed Central PMCID: PMC4546455.

10: Ritter CS, Zhang S, Delmez J, Finch JL, Slatopolsky E. Differential
expression and regulation of Klotho by paricalcitol in the kidney, parathyroid,
and aorta of uremic rats. Kidney Int. 2015 Jun;87(6):1141-52. doi:
10.1038/ki.2015.22. Epub 2015 Feb 18. PubMed PMID: 25692955; PubMed Central
PMCID: PMC4449811.

11: Trillini M, Cortinovis M, Ruggenenti P, Reyes Loaeza J, Courville K,
Ferrer-Siles C, Prandini S, Gaspari F, Cannata A, Villa A, Perna A, Gotti E,
Caruso MR, Martinetti D, Remuzzi G, Perico N. Paricalcitol for secondary
hyperparathyroidism in renal transplantation. J Am Soc Nephrol. 2015
May;26(5):1205-14. doi: 10.1681/ASN.2013111185. Epub 2014 Sep 5. PubMed PMID:
25194004; PubMed Central PMCID: PMC4413751.

12: Akizawa T, Akiba T, Hirakata H, Kinugasa E, Tominaga Y, Fukagawa M, Yokoyama
K, Zhang W, Linde PG, Suzuki M. Comparison of paricalcitol with maxacalcitol
injection in Japanese hemodialysis patients with secondary hyperparathyroidism.
Ther Apher Dial. 2015 Jun;19(3):225-34. doi: 10.1111/1744-9987.12242. Epub 2014
Nov 3. PubMed PMID: 25363733.

13: Nuijten M, Roggeri DP, Roggeri A, Novelli P, Marshall TS. Health economic
evaluation of paricalcitol(®) versus cinacalcet + calcitriol (oral) in Italy.
[corrected]. Clin Drug Investig. 2015 Apr;35(4):229-38. doi:
10.1007/s40261-014-0264-4. Erratum in: Clin Drug Investig. 2015 May;35(5):341.
PubMed PMID: 25724153.

14: Thethi TK, Bajwa MA, Ghanim H, Jo C, Weir M, Goldfine AB, Umpierrez G,
Desouza C, Dandona P, Fang-Hollingsworth Y, Raghavan V, Fonseca VA. Effect of
paricalcitol on endothelial function and inflammation in type 2 diabetes and
chronic kidney disease. J Diabetes Complications. 2015 Apr;29(3):433-7. doi:
10.1016/j.jdiacomp.2015.01.004. Epub 2015 Jan 13. PubMed PMID: 25633573; PubMed
Central PMCID: PMC4392813.

15: Pisani A, Sabbatini M, Duro G, Colomba P, Riccio E. Antiproteinuric effect of
add-on paricalcitol in Fabry disease patients: a prospective observational study.
Nephrol Dial Transplant. 2015 Apr;30(4):661-6. doi: 10.1093/ndt/gfu273. Epub 2014
Aug 20. PubMed PMID: 25143556.

16: Nuijten M, Roggeri DP, Roggeri A, Novelli P, Marshall TS. Erratum to: Health
Economic Evaluation of Paricalcitol(®) Versus Cinacalcet + Calcitriol (Oral) in
Italy. Clin Drug Investig. 2015 May;35(5):341. doi: 10.1007/s40261-015-0284-8.
PubMed PMID: 25808395.

17: Hotha KK, Mullangi R, Lakshmanarao Krishnarao R, Roychowdhury S. Sensitive
method for the determination of paricalcitol by liquid chromatography and mass
spectrometry and its application to a clinical pharmacokinetic study. Biomed
Chromatogr. 2015 Mar;29(3):452-8. doi: 10.1002/bmc.3296. Epub 2014 Aug 6. PubMed
PMID: 25098404.

18: Martinez-Fernandez I, Saracho R. Effects of paricalcitol on urinary calcium
in patients with chronic kidney disease stages 2 - 4. Clin Nephrol. 2015
Apr;83(4):201-7. doi: 10.5414/CN108306. PubMed PMID: 25707454.

19: Diez ER, Altamirano LB, García IM, Mazzei L, Prado NJ, Fornes MW, Carrión FD,
Zumino AZ, Ferder L, Manucha W. Heart remodeling and ischemia-reperfusion
arrhythmias linked to myocardial vitamin d receptors deficiency in obstructive
nephropathy are reversed by paricalcitol. J Cardiovasc Pharmacol Ther. 2015
Mar;20(2):211-20. doi: 10.1177/1074248414538704. Epub 2014 Jun 12. PubMed PMID:
24924917.

20: Stavenuiter AW, Farhat K, Vila Cuenca M, Schilte MN, Keuning ED, Paauw NJ,
ter Wee PM, Beelen RH, Vervloet MG. Protective Effects of Paricalcitol on
Peritoneal Remodeling during Peritoneal Dialysis. Biomed Res Int.
2015;2015:468574. doi: 10.1155/2015/468574. Epub 2015 Oct 29. PubMed PMID:
26605330; PubMed Central PMCID: PMC4641933.